<DOC>
	<DOCNO>NCT02828878</DOCNO>
	<brief_summary>Interventional , open label , Phase I/II , Safety Proof-of-Concept Study , follow period 180 day transplantation ApoGraft .</brief_summary>
	<brief_title>Prevention Acute Graft Versus Host Disease Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation</brief_title>
	<detailed_description>ApoGraft product mobilize peripheral blood cell product match Related donor , collect via apheresis , expose apoptotic mediator Fas Ligand ( CD95L ) prior transplantation . The study design address aspect engraftment Prevention Acute Graft versus Host Disease ( aGvHD ) rate and/or severity 12 Patients STUDY DESIGN : open label , linear four-cohorts consist 3 patient . The study consist screen phase ( subject donor clinical assessment screen test ) , transplantation ApoGraft , follow-up period 180 day hospitalization . Cohorts ' differentiation escalate concentration apoptotic mediator Fas Ligand transplant expose incubation prior transplantation , range 10 ng/ml first cohort 100 ng/ml fourth cohort . The study progress one cohort next base DSMB analysis safety data .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>1 . Adult male female subject , 1870 year age . 2 . Subjects eligible allogeneic HLAmatched related HSCT hematological malignancy transplantation appropriate correspond relate donor . 3 . The donor recipient must full match HLA A , B , C , DR DQ locus . 4 . Life expectancy least 6 month time baseline visit . 5 . ECOG performance status score 01 time screen visit . 6 . Cardiac leave ventricular ejection fraction ≥ 40 % adult within 4 week initiation conditioning . 7 . Pulmonary function test DLCO , FEV1 FVC ≥ 50 % . 8 . Oxygen saturation ≥ 90 % room air . 9 . Subjects must adequate organ function define : AST ( SGOT ) /ALT ( SGPT ) ≤ 2.5 x upper limit normal ( ULN ) . Serum creatinine &lt; 2.5 mg/dL . Serum bilirubin &lt; 3 mg/dL . 10 . Signed write informed consent participate study independently subject . Subjects require guardian sign inform consent include . 11 . Donor criterion accord standard WMDA criterion donor selection . Signed write informed consent donor include consent 2nd donation ApoGraft fail . 12 . Ability comply requirement study . 13 . If female childbearing potential , agree use acceptable method birth control surgically sterile , negative pregnancy test . 1 . Participation investigational trial within 30 day screen visit . 2 . Progressive poorly control malignancy . 3 . Tcell deplete allograft . 4 . Use nonmyeloabletive conditioning . 5 . Uncontrolled infection include sepsis , pneumonia hypoxemia , persistent bacteremia , meningitis within two week screen visit . 6 . Current know acute chronic infection HBV HCV . 7 . Known human immunodeficiency virus ( HIV ) infection AIDS . 8 . Subjects severe symptomatic restrictive obstructive lung disease respiratory failure require ventilator support . 9 . Subjects concurrent severe and/or uncontrolled medical condition , could compromise participation study ( i.e . active infection , uncontrolled diabetes , uncontrolled hypertension , congestive cardiac failure , unstable angina , ventricular arrhythmia , active ischemic heart disease , myocardial infarction within six month chronic liver renal disease . 10 . Any form substance abuse ( include drug alcohol abuse ) , psychiatric disorder chronic condition susceptible , opinion investigator , interfere conduct study . 11 . Organ allograft previous history allogeneic stem cell transplantation . 12 . Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Apoptosis</keyword>
	<keyword>FAS Ligand</keyword>
	<keyword>Bone marrow transplantation</keyword>
	<keyword>GvHD</keyword>
	<keyword>Stem cell</keyword>
</DOC>